Global Pharmaceutical Contract Manufacturing Industry

NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Move Over Offshoring, Here Comes Nearshoring Rising on the Wave of COVID-19 Disruptions. Pharmaceutical Contract Manufacturing Revenues Slump by -1.4%


Read the full report: https://www.reportlinker.com/p05443575/?utm_source=PRN


The global market for Pharmaceutical Contract Manufacturing is expected to slump by -1.4% in the year 2020 and thereafter recover and grow on the back of newly emerging dynamics to reach US$136.5 billion by the year 2027, trailing a post COVID-19 CAGR 4.6% over the analysis period 2020 through 2027. With the pandemic exposing the weakness of health systems worldwide, governments are stepping up the emphasis and policy led support for strengthening their healthcare infrastructure. Governments worldwide have voiced plans to strengthen healthcare system. Already governments have announced budgetary support to strengthen the health system's response to COVID-19. From stepping up research activities, constructing new hospitals, adding more capacity in the form of additional beds, procuring critical care life support devices such as ventilators to training, hiring healthcare staff, several measures are being implemented. The disruption and chaos unleashed by the pandemic has led pharmaceutical companies to rethink their supply chains and outsourcing strategies. The pandemic's impact on pharma supply chains was largely evident in the broken and stranded logistics as countries world over closed their borders, although late to prevent the further spread of the infection. Complete disruption and halting of the transportation and logistics sector temporarily impacted pharmaceutical drug production in countries heavily dependent on imports for active pharmaceutical ingredients (APIs).

The pandemic has exposed the risk of over dependence on a single country for raw materials. China supplies a lion's share of pharma raw materials demanded worldwide. For several antibiotics and drugs that treat high blood pressure, China is the sole source of API in the country. Over the last decade, the number of facilities in China supplying active pharmaceutical ingredients (APIs) to the U.S. alone has doubled since 2010 highlighting the blunder made by the U.S. government in prioritizing the Chinese manufacturing industry over its own. In addition, decisions take by governments to ban exports of certain high value and critically important ingredients in a proactive move to mitigate drug and medical device supply shortages in domestic markets. In the world's most populous country India, for instance, fears over the pandemic spread and anticipated increase in demand for drugs the led the Indian government to ban the exports of over 26 pharma ingredients. These protectionist trade policies aimed at securing domestic pharmaceutical supplies has severely undermined global equitable drug availability and access. Supply chain management over the long-term is in for some of the biggest changes not witnessed in over a century. Countries world over are encouraging pharma companies to secure themselves against volatility in supplies from Asia and from China in particular.

While an immediate shift in pharmaceutical chemical supply lines is not a pragmatic possibility, the change is expected to gradually sink in. Spearheading the new self-sufficient sentiment in the global drug manufacturing space is India, country which is ambitiously focused on turning a crisis into an opportunity by rethinking and rejuvenating its pharmaceutical supply chain management practices and ideologies. Going forward over the long-term decisions to outsource manufacturing activities will be governed by more than just cost efficiency benefit. As companies emerge wiser from the lessons taught by the pandemic outsourcing drug manufacturing will mean greater focus will be shed on maintaining good reactive capacity close to where it is needed. Also, companies will now begin to outsource manufacturing to multiple countries and regions to ensure resilience in case of disasters similar to the current healthcare crisis or natural disasters. Until now, pharma companies have leveraged outsourcing as a great way to take advantage of cheap labor and raw materials available in countries like China. As the world tries to disengage dependence on China, nearshoring as a sub-set of offshoring is gaining whole new significance and reenergized focus. The closer manufacturing partners are to the home country, greater will be level of control over quality and lesser will be vulnerability to disruptions. Communication becomes easier, time-to-market is significantly reduced, chances of errors and product recalls become smaller, and control, flexibility and agility are increased x times. Vulnerability to transport disruptions also becomes significantly lower. Also nearshoring to contract manufacturers in the same time zone means lesser regulatory bottlenecks. In addition to protecting against unforeseen disaster scenarios and disruptions, nearshoring also reduces quality defects, random interruptions in manufacturing processes, order processing difficulties, untimely delivery of products and mismatch between market demand and supplier responsiveness. Nearshoring is increasingly perceived to be a part of the bigger reshoring trend set into motion by the COVID-19 pandemic. In addition, to mitigate the effects of supply chain disruptions, pharmaceutical companies are increasingly recalibrated their strategies by greater insourcing and nearshoring of core products, and outsourcing non-core products and developing offshore insourcing capabilities through 'captives'. The B2G is poised to balloon into a major trend as public-private partnerships come to the spotlight as countries initiate policy changes to bring back domestic production.

Competitors identified in this market include, among others,

• Aenova Group
• Ajinomoto Althea, Inc.
• Albany Molecular Research Inc.
• Alcami Corporation
• Baxter International, Inc.
• Boehringer Ingelheim GmbH
• Catalent Pharma Solutions, Inc.
• Cobra Biologics Holding AB
• CordenPharma International
• Dishman Group
• Famar Health Care Services
• Hospira, Inc.
• Jubilant Life Sciences Limited
• Kemwell Biopharma Pvt. Ltd.
• Lonza Group Ltd.
• LTS Lohmann Therapie-Systeme AG
• NextPharma Technologies Holding Ltd.
• Nipro Pharma Corporation
• Recipharm AB
• Vetter Pharma International GmbH

Read the full report: https://www.reportlinker.com/p05443575/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXE7CUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1
Pharmaceutical Contract Manufacturing - A Prelude II-1
Impact of Covid-19 and a Looming Global Recession II-1
COVID-19 Breaks All Things Normal, Pushes Pharmaceutical
Industry into an Era of Change II-1
COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply
Shortages II-2
US Federal Government & FDA Take Unprecedented, Bold Steps to
Deal with Shortage of Pharmaceuticals II-3
What Does this Spell for Pharmaceutical Outsourcing & Contract
Manufacturing? II-3
Market Outlook II-5
The US and Europe Constitute the Largest Markets for PCM II-6
Asia-Pacific to Drive the PCM Market Growth II-6
Competition II-6
M&A Activity High in the Contract Manufacturing Space II-7

2. FOCUS ON SELECT PLAYERS II-9
Recent Market Activity II-13

3. MARKET TRENDS & DRIVERS II-15
Strong Rise in Pharmaceutical Sales to Drive Demand for
Pharmaceutical Contract Manufacturing II-15
Exhibit 1: Global Prescription Drug Sales (In US$ Billion) for
the Years 2017, 2019, 2021, 2023 & 2025 II-16
Emergence of Outsourcing Trend Bodes Well for CDMOs II-16
Pharmaceutical Contract Manufacturers Adopt Advanced
Manufacturing Technologies II-17
Embracing Emerging Technologies II-18
Exploring & Exploiting New Technologies for Rich Dividends II-19
Rapid Growth of Generic Drugs Drives Demand for Pharma Contract
Manufacturing II-19
Exhibit 2: Leading Drugs Facing Patent Expiry in the US in 2020 II-21
Exhibit 3: Global Generic Drugs Market Size (in $ Billion) for
the Years 2016, 2019, 2020 & 2025 II-21
Increasing Significance of Biologic Drugs Supports Market Demand II-21
Exhibit 4: Global Biologic Drugs Market Size (in US$ Billion)
for the Years 2019, 2022 & 2025 II-22
Aging Population & Increasing Burden of Chronic Diseases Spurs
Pharma Product Sales, Driving Market Growth II-23
Exhibit 5: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050 II-24
Exhibit 6: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-25
Exhibit 7: World Diabetes and Population Statistics (2019,
2030 & 2045) II-25
Persistent Increase in Pharmaceutical R&D Bodes Well for PCM II-25
Exhibit 8: Pharmaceutical R&D Spending Worldwide (USD Billion):
2015-2025 II-26
Increasing Sales of OTC Drugs Presents an Opportunity for
Pharma Contract Manufacturing Market II-27
Exhibit 9: Global OTC Drugs Market Breakdown by Product (in %):
2020E II-27
Increasing Outsourcing of Clinical Trials to Emerging Markets II-28
New Technology Promises to Improve Sterile Manufacturing Process II-28
Serialization Drives New Design Developments in Pharma Sector II-29

4. GLOBAL MARKET PERSPECTIVE II-30
Table 1: World Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 II-30

Table 2: World Historic Review for Pharmaceutical Contract
Manufacturing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 II-31

Table 3: World 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2012, 2020 & 2027 II-32

Table 4: World Current & Future Analysis for API/Bulk Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-33

Table 5: World Historic Review for API/Bulk Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 II-34

Table 6: World 15-Year Perspective for API/Bulk Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-35

Table 7: World Current & Future Analysis for Advanced Drug
Delivery Formulations by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 II-36

Table 8: World Historic Review for Advanced Drug Delivery
Formulations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 II-37

Table 9: World 15-Year Perspective for Advanced Drug Delivery
Formulations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027 II-38

Table 10: World Current & Future Analysis for Packaging by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-39

Table 11: World Historic Review for Packaging by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 II-40

Table 12: World 15-Year Perspective for Packaging by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027 II-41

Table 13: World Current & Future Analysis for Finished Dose
Formulations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 II-42

Table 14: World Historic Review for Finished Dose Formulations
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-43

Table 15: World 15-Year Perspective for Finished Dose
Formulations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027 II-44

Table 16: World Current & Future Analysis for Other Product
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-45

Table 17: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-46

Table 18: World 15-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-47

Table 19: World Current & Future Analysis for Pharmaceutical by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-48

Table 20: World Historic Review for Pharmaceutical by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-49

Table 21: World 15-Year Perspective for Pharmaceutical by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-50

Table 22: World Current & Future Analysis for Biopharmaceutical
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-51

Table 23: World Historic Review for Biopharmaceutical by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-52

Table 24: World 15-Year Perspective for Biopharmaceutical by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-53

Table 25: World Current & Future Analysis for Sterile by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-54

Table 26: World Historic Review for Sterile by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 II-55

Table 27: World 15-Year Perspective for Sterile by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027 II-56

Table 28: World Current & Future Analysis for Non-Sterile by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-57

Table 29: World Historic Review for Non-Sterile by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 II-58

Table 30: World 15-Year Perspective for Non-Sterile by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-59

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1
Table 31: USA Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-1

Table 32: USA Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-2

Table 33: USA 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2020 & 2027 III-3

Table 34: USA Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Application - Pharmaceutical and
Biopharmaceutical - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 III-4

Table 35: USA Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-5

Table 36: USA 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Pharmaceutical and Biopharmaceutical for the Years
2012, 2020 & 2027 III-6

Table 37: USA Current & Future Analysis for Pharmaceutical
Contract Manufacturing by End-Use - Sterile and Non-Sterile -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-7

Table 38: USA Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 III-8

Table 39: USA 15-Year Perspective for Pharmaceutical Contract
Manufacturing by End-Use - Percentage Breakdown of Value Sales
for Sterile and Non-Sterile for the Years 2012, 2020 & 2027 III-9

CANADA III-10
Table 40: Canada Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-10

Table 41: Canada Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-11

Table 42: Canada 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2020 & 2027 III-12

Table 43: Canada Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Application - Pharmaceutical and
Biopharmaceutical - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 III-13

Table 44: Canada Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-14

Table 45: Canada 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2020 & 2027 III-15

Table 46: Canada Current & Future Analysis for Pharmaceutical
Contract Manufacturing by End-Use - Sterile and Non-Sterile -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-16

Table 47: Canada Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 III-17

Table 48: Canada 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2020 & 2027 III-18

JAPAN III-19
Table 49: Japan Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-19

Table 50: Japan Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-20

Table 51: Japan 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2020 & 2027 III-21

Table 52: Japan Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Application - Pharmaceutical and
Biopharmaceutical - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 III-22

Table 53: Japan Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-23

Table 54: Japan 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Pharmaceutical and Biopharmaceutical for the Years
2012, 2020 & 2027 III-24

Table 55: Japan Current & Future Analysis for Pharmaceutical
Contract Manufacturing by End-Use - Sterile and Non-Sterile -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-25

Table 56: Japan Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 III-26

Table 57: Japan 15-Year Perspective for Pharmaceutical Contract
Manufacturing by End-Use - Percentage Breakdown of Value Sales
for Sterile and Non-Sterile for the Years 2012, 2020 & 2027 III-27

CHINA III-28
Table 58: China Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-28

Table 59: China Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-29

Table 60: China 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2020 & 2027 III-30

Table 61: China Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Application - Pharmaceutical and
Biopharmaceutical - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 III-31

Table 62: China Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-32

Table 63: China 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Pharmaceutical and Biopharmaceutical for the Years
2012, 2020 & 2027 III-33

Table 64: China Current & Future Analysis for Pharmaceutical
Contract Manufacturing by End-Use - Sterile and Non-Sterile -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-34

Table 65: China Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 III-35

Table 66: China 15-Year Perspective for Pharmaceutical Contract
Manufacturing by End-Use - Percentage Breakdown of Value Sales
for Sterile and Non-Sterile for the Years 2012, 2020 & 2027 III-36

EUROPE III-37
Table 67: Europe Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 III-37

Table 68: Europe Historic Review for Pharmaceutical Contract
Manufacturing by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-38

Table 69: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2012, 2020 & 2027 III-39

Table 70: Europe Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-40

Table 71: Europe Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-41

Table 72: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2020 & 2027 III-42

Table 73: Europe Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Application - Pharmaceutical and
Biopharmaceutical - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 III-43

Table 74: Europe Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-44

Table 75: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2020 & 2027 III-45

Table 76: Europe Current & Future Analysis for Pharmaceutical
Contract Manufacturing by End-Use - Sterile and Non-Sterile -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-46

Table 77: Europe Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 III-47

Table 78: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2020 & 2027 III-48

FRANCE III-49
Table 79: France Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-49

Table 80: France Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-50

Table 81: France 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2020 & 2027 III-51

Table 82: France Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Application - Pharmaceutical and
Biopharmaceutical - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 III-52

Table 83: France Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-53

Table 84: France 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2020 & 2027 III-54

Table 85: France Current & Future Analysis for Pharmaceutical
Contract Manufacturing by End-Use - Sterile and Non-Sterile -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-55

Table 86: France Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 III-56

Table 87: France 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2020 & 2027 III-57

GERMANY III-58
Table 88: Germany Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-58

Table 89: Germany Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-59

Table 90: Germany 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2020 & 2027 III-60

Table 91: Germany Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Application - Pharmaceutical and
Biopharmaceutical - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 III-61

Table 92: Germany Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-62

Table 93: Germany 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2020 & 2027 III-63

Table 94: Germany Current & Future Analysis for Pharmaceutical
Contract Manufacturing by End-Use - Sterile and Non-Sterile -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-64

Table 95: Germany Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 III-65

Table 96: Germany 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2020 & 2027 III-66

ITALY III-67
Table 97: Italy Current & Future Analysis for Pharmaceutical
Contract Manufacturing by Product Type - API/Bulk Drugs,
Advanced Drug Delivery Formulations, Packaging, Finished Dose
Formulations and Other Product Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 III-67

Table 98: Italy Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 III-68

Table 99: Italy 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05443575/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com  
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-pharmaceutical-contract-manufacturing-industry-301180497.html

SOURCE Reportlinker